Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Aurinia Pharmaceuticals: Will AURORA Light The Way To Voclosporin's Approval?

2018-02-16 seekingalpha
As many as 500,000 patients suffer from Systemic Lupus Erythematosus ((SLE)) in the USA, 60% of whom will develop Lupus Nephritis ((LN)) and there are no licenced treatments. (247-0)

Aurinia Pharmaceuticals: Potential Rewards Far Outweigh The Risks

2018-01-26 seekingalpha
Aurnia Pharmaceuticals (AUPH) is a clinical stage biopharmaceutical company with a lead product candidate targeting an area where there's a major unmet need. The lead candidate, voclosporin, already has shown a great deal of promise in Phase II stage. Aurinia Pharmaceuticals’ valuation though continues to paint a completely different picture. The current valuation reflects investors’ concern over voclosporin patents. (247-6)

Aurinia Pharmaceuticals' Voclosporin: A Blockbuster Drug Hidden In Plain Sight?

2018-01-25 seekingalpha
Pharmaceutical giants will have to pay up for the opportunity to acquire a blockbuster asset like Voclosporin. (250-4)

A Breakout in Aurinia Pharmaceuticals Inc May Be Imminent

2018-01-19 investorplace
The downtrend in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) may end soon — not from the renewed interest in biotech stocks but because of Aurina’s upcoming revenue potential. (521-10)

Canadian Exchanges Stock Scanner Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International

2017-12-14 accesswire
LONDON, UK / ACCESSWIRE / December 14, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International. Access our complimentary up-to-the-minute research reports by becoming an online member now: (268-6)

Addressing Concerns With Aurinia Pharmaceuticals COO Michael Martin

2017-11-30 seekingalpha
Why Aurinia is putting VOS up against Restasis over XIIDRA despite arguably better data from XIIDRA. (318-23)

3 Reasons To Buy Aurinia Pharmaceuticals

2017-11-24 seekingalpha
Voclosporin, a potential blockbuster drug, revealed convincing phase 2 data for treatment of lupus nephritis and is being piloted toward dry eye disease. (247-13)

Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q3 2017 Results - Earnings Call Transcript

2017-11-15 seekingalpha
Greetings and welcome to the Aurinia Pharmaceuticals Incorporated Third Quarter 2017 Financial Results. At this time, all participants are in listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (247-6)

Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?

2017-11-13 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Aurinia Pharmaceuticals Inc. (AUPH - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Aurinia Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. (247-9)

Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International

2017-11-08 accesswire
LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Biotechnology industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International. (268-6)

Park Hotels' Yield Is Good - Cramer's Lightning Round (11/3/17)

2017-11-06 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, November 3. (248-3)

Cramer Remix: Wait to hear Nvidia’s earnings before buying the stock

2017-11-03 cnbc
CNBC's Jim Cramer told investors to hang on to the stock market's "benign" action on Friday ahead of another potentially raucous week of earnings. (291-0)

Cramer's lightning round: I'm concerned about GameStop

2017-11-03 cnbc
GameStop Corp.: "I am concerned about GameStop. I have to tell you, if they're going to sell EA down and they're going to sell Activision Blizzard down… It's going to be a very digital holiday season, and to me, that means that's bad for GameStop, so I'm going to have to say don't buy." (286-0)

AUPH / Aurinia Pharmaceuticals Inc - Stock Institutional Ownership and Shareholders -

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has 69 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 28,973,973 shares. Largest shareholders include FMR LLC / Fidelity Management & Research, Duggan Robert W, NEA Management Company, LLC, Orbimed Advisors Llc, and Franklin Resources Inc. (279-17)